冠状动脉旁路移植术后二级预防的预后影响——来自TiCAB试验的见解
基于TiCAB随机试验数据,2013年4月至2017年4月纳入CABG患者,比较接受最佳二级预防与缺少一种或以上推荐药物的患者。12个月随访1807例,仅54%接受最佳二级预防;最佳预防组全因死亡、心血管死亡和主要不良事件均显著低于非最佳组。
要点
- CABG术后仅约半数(54%)患者接受最佳二级预防。
- 最佳二级预防组全因死亡率0.5% vs 3.5%,HR 0.14(0.05-0.37),P<0.01。
- 最佳二级预防组主要不良事件6.5% vs 11.5%,HR 0.54(0.39-0.74),P<0.01。
核心结论
- CABG术后仅每两名患者中有一名接受最佳二级预防。
- 遵循指南的二级预防治疗与12个月后较低的死亡率和较少的不良心血管事件相关。
研究设计与样本
- 数据来自随机试验「Ticagrelor in CABG」,2013年4月至2017年4月纳入接受CABG的患者。
- 本分析比较接受最佳药物二级预防的患者与缺少一种或以上推荐药物的患者。
- 12个月随访数据共1807例患者。
主要发现
- 1807例患者中约半数(54%)接受最佳二级预防。
- 最佳二级预防组 vs 非最佳组:全因死亡率0.5% vs 3.5%,HR 0.14(0.05-0.37),P<0.01。
- 最佳二级预防组 vs 非最佳组:心血管死亡率0.1% vs 1.7%,HR 0.06(0.01-0.46),P=0.007。
- 最佳二级预防组 vs 非最佳组:主要不良事件6.5% vs 11.5%,HR 0.54(0.39-0.74),P<0.01。
- 基于二分类指南推荐治疗依从性的主要终点多变量模型识别出3个独立因素:指南推荐治疗依从性HR 0.55(0.39-0.78),P<0.001;肾功能正常HR 0.99(0.98-0.99),P=0.040;非体外循环手术HR 2.06(1.02-4.18),P=0.045。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG. METHODS: Data were taken from the randomized 'Ticagrelor in CABG' trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing. RESULTS: Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05-0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01-0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39-0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39-0.78), P < 0.001]; normal renal function [HR 0.99 (0.98-0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02-4.18), P = 0.045]. CONCLUSIONS: Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.
引用
- Heer T, von Scheidt M, Boening A, et al. Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. Eur J Cardiothorac Surg. 2022. PMID: 35138350. doi:10.1093/ejcts/ezac048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。